How many 8-K filings has Vyome Holdings, Inc filed?

Vyome Holdings, Inc (HIND) has 34 8-K (Current Event Report) filings on record, spanning Jan 2024 to Dec 2025.

What is a 8-K filing?

A 8-K is an SEC filing known as "Current Event Report." Filed to announce significant events or material changes such as acquisitions, executive departures, earnings announcements, or bankruptcy filings.

Where can I read Vyome Holdings, Inc 8-K filings in plain English?

ReadTheFiling provides AI-powered plain-English summaries of all Vyome Holdings, Inc 8-K filings, including risk assessment, sentiment analysis, and key financial figures.

Vyome Holdings, Inc (HIND) — 8-K Filings

All 8-K filings from Vyome Holdings, Inc. Browse 34 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (34)

8-K Filing — Dec 23, 2025
Vyome Holdings Files 8-K on Financials — Nov 19, 2025 Risk: low
Vyome Holdings, Inc. filed an 8-K on November 19, 2025, reporting on its financial condition and results of operations as of November 18, 2025. The filing indic
Vyome Holdings Files 8-K on Shareholder Vote Matters — Oct 30, 2025 Risk: low
Vyome Holdings, Inc. filed an 8-K on October 30, 2025, reporting on matters submitted to a vote of security holders as of October 28, 2025. The company, formerl
Vyome Holdings Relocates HQ to Cambridge, MA — Oct 3, 2025 Risk: low
Vyome Holdings, Inc. filed an 8-K on October 3, 2025, reporting an event on September 29, 2025. The filing indicates a change in the company's principal executi
Vyome Holdings Files 8-K — Sep 2, 2025 Risk: low
Vyome Holdings, Inc. filed an 8-K on September 2, 2025, reporting on other events and financial statements. The company, formerly known as ReShape Lifesciences
Vyome Holdings Files 8-K: Material Agreement & Accountant Change — Aug 20, 2025 Risk: medium
Vyome Holdings, Inc. filed an 8-K on August 20, 2025, reporting a material definitive agreement and changes in its certifying accountant. The filing date indica
Vyome Holdings Reports Asset Deal, Equity Sales, and Governance Changes — Aug 19, 2025 Risk: medium
Vyome Holdings, Inc. reported on August 13, 2025, a completion of an acquisition or disposition of assets. The company also disclosed unregistered sales of equi
ReShape Lifesciences Files 8-K on Shareholder Vote Matters — Aug 11, 2025 Risk: low
ReShape Lifesciences Inc. filed an 8-K on August 11, 2025, reporting a submission of matters to a vote of security holders on August 7, 2025. The company, forme
ReShape Lifesciences Files 8-K on Shareholder Vote — Jul 25, 2025 Risk: low
ReShape Lifesciences Inc. filed an 8-K on July 25, 2025, reporting on a matter submitted to a vote of security holders on July 24, 2025. The company, formerly k
ReShape Lifesciences Files 8-K Report — Jul 15, 2025 Risk: low
On July 15, 2025, ReShape Lifesciences Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. T
ReShape Lifesciences Inc. Signs Material Definitive Agreement — Jul 3, 2025 Risk: medium
On June 27, 2025, ReShape Lifesciences Inc. entered into a material definitive agreement. The filing does not provide specific details on the agreement's nature
ReShape Lifesciences Relocates Principal Executive Offices — Jun 18, 2025 Risk: low
On June 18, 2025, ReShape Lifesciences Inc. filed an 8-K report. The filing indicates a change in the company's principal executive offices to 18 Technology Dri
ReShape Lifesciences Inc. Files 8-K for Material Agreement — Jun 12, 2025 Risk: medium
On June 8, 2025, ReShape Lifesciences Inc. entered into a material definitive agreement. The filing also includes Regulation FD disclosures and financial statem
ReShape Lifesciences Relocates Headquarters — Jun 9, 2025 Risk: low
On June 9, 2025, ReShape Lifesciences Inc. filed an 8-K report. The filing indicates a change in the company's principal executive offices to 18 Technology Driv
ReShape Lifesciences Faces Delisting Concerns — May 30, 2025 Risk: high
ReShape Lifesciences Inc. filed an 8-K on May 30, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard as of May 28,
ReShape Lifesciences Inc. Files 8-K Report — May 28, 2025 Risk: low
On May 28, 2025, ReShape Lifesciences Inc. filed an 8-K report. The filing indicates the company's principal executive offices are located at 18 Technology Driv
ReShape Lifesciences Files 8-K on Security Holder Rights — May 9, 2025 Risk: medium
On May 6, 2025, ReShape Lifesciences Inc. filed an 8-K report detailing material modifications to security holder rights and amendments to its articles of incor
ReShape Lifesciences Inc. Signs Material Definitive Agreement — Apr 28, 2025 Risk: medium
On April 25, 2025, ReShape Lifesciences Inc. entered into a material definitive agreement. The filing does not provide specific details on the agreement's natur
ReShape Lifesciences Inc. Signs Material Definitive Agreement — Apr 21, 2025 Risk: medium
On April 15, 2025, ReShape Lifesciences Inc. entered into a material definitive agreement. The filing does not provide specific details on the agreement's natur
ReShape Lifesciences Files 8-K on Shareholder Vote Matters — Apr 2, 2025 Risk: medium
ReShape Lifesciences Inc. filed an 8-K on April 2, 2025, reporting on matters submitted to a vote of security holders as of April 1, 2025. The filing indicates
ReShape Lifesciences Announces Executive and Board Changes — Mar 20, 2025 Risk: medium
On March 14, 2025, ReShape Lifesciences Inc. announced the departure of its Chief Financial Officer, Paul E. Savory. The company also reported the appointment o
ReShape Lifesciences Inc. Files 8-K: Material Agreement — Feb 20, 2025 Risk: medium
On February 15, 2025, ReShape Lifesciences Inc. entered into a material definitive agreement. The filing also includes Regulation FD Disclosure and Financial St
ReShape Lifesciences Enters Material Definitive Agreement — Jan 21, 2025 Risk: medium
On January 14, 2025, ReShape Lifesciences Inc. entered into a material definitive agreement. The company, formerly known as Obalon Therapeutics Inc., is incorpo
ReShape Lifesciences Files 8-K with Material Agreement — Dec 27, 2024 Risk: medium
On December 19, 2024, ReShape Lifesciences Inc. entered into a material definitive agreement, the details of which are not fully disclosed in this filing. The c
ReShape Lifesciences Files 8-K — Dec 11, 2024 Risk: low
On December 11, 2024, ReShape Lifesciences Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibit
ReShape Lifesciences Faces Nasdaq Delisting — Dec 2, 2024 Risk: high
ReShape Lifesciences Inc. received a notice on November 25, 2024, indicating it failed to meet the continued listing standards of The Nasdaq Stock Market LLC. T
ReShape Lifesciences Inc. Reports Material Definitive Agreement and Equity Sales — Oct 17, 2024 Risk: medium
On October 16, 2024, ReShape Lifesciences Inc. entered into a material definitive agreement related to the creation of a direct financial obligation. The compan
ReShape Lifesciences to be Acquired by HealthBeacon Affiliate — Sep 24, 2024 Risk: medium
ReShape Lifesciences Inc. announced on September 18, 2024, that it has entered into a definitive agreement to be acquired by an affiliate of HealthBeacon Ltd. f
ReShape Lifesciences Sells Lap-Band Assets, Appoints New Directors — Jul 9, 2024 Risk: medium
ReShape Lifesciences Inc. announced on July 8, 2024, a material definitive agreement related to the sale of its Lap-Band assets to an undisclosed buyer for an u
ReShape Lifesciences Files 8-K on Financials — May 20, 2024 Risk: low
ReShape Lifesciences Inc. filed an 8-K on May 15, 2024, reporting on its results of operations and financial condition. The filing includes financial statements
ReShape Lifesciences Appoints New Auditor Amidst Accounting Disagreements — Apr 10, 2024 Risk: medium
ReShape Lifesciences Inc. announced on April 8, 2024, that it has appointed BDO USA, LLP as its new independent registered public accounting firm, replacing the
ReShape Lifesciences Files 8-K for Operations Update — Apr 4, 2024 Risk: low
On April 1, 2024, ReShape Lifesciences Inc. filed an 8-K report detailing its financial results and operations. The company, formerly known as Obalon Therapeuti
ReShape Lifesciences Files 8-K on Shareholder Vote Submission — Feb 26, 2024 Risk: medium
ReShape Lifesciences Inc. filed an 8-K on February 26, 2024, reporting an event that occurred on February 23, 2024. The filing, under SEC File Number 001-37897,
ReShape Lifesciences Faces Delisting Risk, Amends Bylaws — Jan 18, 2024
ReShape Lifesciences Inc. filed an 8-K on January 18, 2024, reporting events from January 11, 2024, related to a notice of delisting or failure to satisfy conti

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX